<DOC>
	<DOCNO>NCT02196857</DOCNO>
	<brief_summary>The goal clinical research study learn 5-azacitidine sorafenib help control disease patient AML high risk MDS FLT3-ITD mutation . The safety drug combination also study .</brief_summary>
	<brief_title>Sorafenib Plus 5-Azacitidine Initial Therapy Patients With Acute Myeloid Leukemia ( AML ) High Risk Myelodysplastic Syndrome ( MS ) With FLT3-ITD Mutation</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive 5-azacitidine either injection skin vein Days 1-7 28-day cycle . If vein , infusion take 10-40 minute . You take sorafenib mouth 2 time day 12 hour apart , least 1 cup ( 8 ounce ) water empty stomach , every day . If vomit dose , make . You wait take next schedule dose . Each study cycle may last little long 28 day , depend . Study Visits : Each week , blood ( 1 tablespoon ) drawn routine test . Each week first 6 week , often doctor think need , blood pressure measure . Before cycle , physical exam . Before every 2-4 cycle , bone marrow aspirate check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . End-of-Study Visit : After stop take study drug , follow test procedure perform : - You physical exam . - You bone marrow aspirate check status disease . - Blood ( 2 tablespoon ) draw routine test . Follow-Up Visits : After end-of-study visit , return clinic every 3 month follow test procedure : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . This investigational study . Sorafenib FDA approve commercially available treatment kidney cancer liver cancer . 5-azacitidine FDA approve treatment MDS , combine sorafenib investigational . The study doctor tell study drug design work . Up 52 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients untreated AML ( &gt; equal 20 % blast bone marrow and/or peripheral blood ) high risk MDS ( &gt; equal 10 % blast bone marrow ) . A . Patients AML history MDS receive prior therapy hypomethylating agent ( include azacytidine ) and/or lenalidomide prior MDS eligible treat physician feel participation study patient ' best interest . B . Patients molecular evidence presence FLT3ITD mutation molecular burden least 10 % . 2 . Age &gt; equal 60 year ; patient younger 60 unsuitable unwilling receive standard cytotoxic chemotherapy also eligible enrol . 3 . ECOG Performance Status &lt; equal 2 . 4 . Adequate liver ( bilirubin &lt; equal 1.5 x ULN , ALT AST &lt; equal 2.5 x ULN Alkaline phosphatase &lt; equal 4 x ULN related leukemic disease ) renal ( creatinine &lt; equal 1.5 x ULN ) function . 5 . Patients must provide write informed consent . 6 . Patients must therapy MDS 2 week prior enter study , must recover toxic effect therapy least grade 1 , unless evidence rapidly progressive disease . Use hydroxyurea ( dose ) araC ( 1 g/m^2 X 2 dos ) patient rapidly proliferative disease allow start study therapy ; stop 24 hour prior initiation azacitidine sorafenib . 7 . Women childbearing potential advise avoid become pregnant adequate method contraception ( barrier hormonal method ) men advise father child receive treatment azacitidine . All men woman childbearing potential must use acceptable method birth control throughout study describe : Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Men use adequate birth control least 30 day last administration sorafenib . Postmenopausal woman ( defined menses least one year ) surgically sterilize woman require undergo pregnancy test . Females childbearing potential : Recommendation 2 effective contraceptive method study . 8 . 7 . Continued : Adequate form contraception doublebarrier method ( condom spermicidal jelly foam diaphragm spermicidal jelly foam ) , oral , depo provera , injectable contraceptive , intrauterine device , tubal ligation . Male patient female partner childbearing potential : Recommendation male partner use least 2 effective contraceptive method , describe , study . 9 . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . 10 . INR &lt; equal 1.5 . Patients receive anticoagulation treatment agent warfarin heparin MAY allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor weekly , define local standard care , INR stable . 1 . Nursing pregnant female . 2 . Patients acute promyelocytic leukemia exclude . 3 . Patients know allergy sorafenib azacitidine , mannitol component . 4 . Patients know severe impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption sorafenib . 5 . Patients know disease ( except carcinoma insitu ) concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes , cardiovascular disease include congestive heart failure , myocardial infarction within 6 month uncontrolled hypertension , chronic renal disease ( creatinine clearance &lt; 20 ml/min use Cockcroft Gault formula ) , active uncontrolled infection ) could compromise participation study . 6 . Patients know confirmed diagnosis HIV infection active viral hepatitis ( B C ) . 7 . Patients major surgical procedure within 28 day prior Day 1 . 8 . Patients unwilling unable comply protocol . 9 . Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . 10 . Uncontrolled hypertension define systolic blood pressure &gt; 150 ? mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . 11 . Active clinically serious infection &gt; CTCAE v4 , Grade 2 control antibiotic . 12 . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 13 . Pulmonary hemorrhage/bleeding event &gt; equal CTCAE v4 . Grade 2 within 4 week first dose study drug . 14 . Any hemorrhage/bleeding event &gt; equal CTCAE v4 . Grade 3 within 4 week first dose study drug . 15 . Serious nonhealing wound , ulcer , bone fracture . 16 . Evidence bleed diathesis coagulopathy within past 6 month . 17 . Known suspected allergy sorafenib agent give course trial . 18 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result include known noncompliance issue study trial . 19 . Use strong CYP3A4 inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>High risk myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>FLT3-ITD mutation</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>5-AZA</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>BAY 43-9006</keyword>
</DOC>